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 Dear Editor, 
 
We have been closely following the proposed diagnostic criteria for Alzheimer’s disease 
(AD) over the last few years (Foster et al., 2008). Recent revisions of the AD criteria 
proposed by Dubois et al. (2010) represent a clear improvement of their previously published 
position paper (Dubois et al., 2007).  In the new revision, Dubois et al. propose an important 
distinction between the clinical disorder (AD), and the neuropathological condition 
(“Alzheimer’s pathology”).  They also describe a number of distinctions within the clinical 
disorder, including two preclinical conditions (“Asymptomatic at-risk for AD” and 
“Presymptomatic AD”), a prodromal condition (“Prodromal AD”), and AD dementia with 
varying presentations (“Typical AD,” “Atypical AD” and “Mixed AD”).  
 
The authors provide an evidence-based structure to improve the clarity of pre-dementia 
conditions; particularly the new classification of individuals previously diagnosed with MCI, 
but with biomarker evidence of AD pathology, as having “Prodromal AD”. However, the 
definitions provided for “Atypical and Mixed AD” may result in some confusion and lack of 
diagnostic clarity. For example, “Atypical AD” refers to the less common clinical features of 
the disease accompanying other clinical syndromes such as primary progressive non-fluent 
aphasia and logopenic aphasia. It should be recognized that in these conditions, AD is not a 
prominent feature of the disease and applying atypical AD as the diagnosis may increase the 
possibility of a misleading or incorrect diagnosis. Further, in the recently suggested frontal 
variant of AD that was mentioned as an example of “Atypical AD” by Dubois et al., the 
antemortem diagnoses is very uncertain (Larner, 2006) and may not be very reliable.   
 
Similarly, the “Mixed AD” refers to a condition where patients must “present with full 
diagnostic criteria of “Typical AD” plus the clinical and pathophysiological evidence of other 
diseases or disorders”. It is unclear what diagnostic, treatment or research benefit is achieved 
with this classification approach rather than simply applying “Typical AD” diagnosis in 
concert with the associated co-morbid diagnosis (e.g. vascular disease).  We believe that 
specifying the co-occurring pathology based on co-morbidity with AD may be more useful 
for the patients’ management. 
 
Most importantly, however, the authors have not acknowledged the importance of including 
“age at onset” as a factor in diagnostic classification.  Specifically, there is a need for 
differential diagnoses of early onset AD (EOAD) versus late onset AD (LOAD).  
Neurochemical and neuropathological differences between EOAD and LOAD have been 
previously reported (Iversen, 1987).  Additionally, age at onset has been shown to influence 
clinical presentation of AD.  Therefore, using the EOAD versus LOAD diagnostic distinction 
may promote differentially effective management approaches for each group of patients 
(Emery and Oxman, 2003). Although, current knowledge about the clinical course of EOAD 
as compared to the LOAD remains incomplete, there are at least three reasons that this 
dichotomy should be included in the diagnostic criteria: 
 
1. The neuropsychological profile for pre and post-diagnostic phases could be different 
for these two groups, with subsequent implications for functional status; 
2. The covariant factors affecting treatment (e.g. other diseases and clinical conditions, 
the medications used by each group of patients, psychosocial support and 
responsibilities, etc.) are likely to vary across the diagnostic groups; 
3. As age at onset may determine the prototype of the disease, incorporating it may 
change the clinical management of the patient, as well as the disease prognosis. 
 
In summary, the revised criteria proposed by Dubois et al. (2010) represent an important step 
forward in the development a “new lexicon for Alzheimer’s disease” for researchers and 
clinicians.  However, further refinement of some diagnostic categories, as well as 
consideration of age of onset as an important clinical feature, are important next steps in this 
endeavor. 
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